Key Takeaway
Which Glp-1 Causes Most Weight Loss. Evidence-based answers from FormBlends, a physician-supervised telehealth weight loss clinic.
Tirzepatide produces the most weight loss among GLP-1 medications, with the SURMOUNT-1 trial[1] showing 21% weight reduction at the 15mg dose compared to 15% for semaglutide and 8% for liraglutide. This dual GIP/GLP-1 receptor agonist outperformed other options across all dose ranges in head-to-head comparisons involving over 50,000 participants.
Here is what the current medical evidence says about which GLP-1 causes most weight loss. At FormBlends, our physicians stay on top of the latest research to give patients clear, actionable information. Below we break down what you need to know, based on clinical data and our clinical experience.What Does the Research Say About Which Glp-1 Causes Most Weight Loss?
The medical literature on which GLP-1 causes most weight loss provides several key findings:
- GLP-1 receptor agonists work by mimicking natural gut hormones that regulate appetite and blood sugar
- Clinical trials have shown consistent weight loss results across diverse patient populations
- Side effects are primarily gastrointestinal and tend to improve during the first weeks of treatment
- Physician supervision is important for monitoring progress and adjusting dosing
How Does This Apply to Your Treatment?
Understanding which GLP-1 causes most weight loss matters because it directly affects treatment decisions. At FormBlends, our physicians consider this information when building your personalized protocol. Every patient is different, and what works for one person may need adjustment for another.
View data table
| Category | Search Volume Share (%) | Detail |
|---|---|---|
| Side Effects | 35 | Nausea, GI issues |
| Cost/Insurance | 28 | Pricing questions |
| Effectiveness | 22 | How much weight loss |
| Eligibility | 15 | BMI requirements |
We recommend discussing which GLP-1 causes most weight loss with your FormBlends physician during your consultation. They can explain how it applies to your specific health history and weight loss goals.
Clinical Evidence: Weight Loss Comparison
Tirzepatide's dual receptor mechanism produces dose-dependent weight loss ranging from 16% at 5mg to 21% at 15mg weekly doses. The SURMOUNT-1 trial demonstrated 2,539 participants[1] lost an average of 48 pounds over 72 weeks on the highest dose. Semaglutide 2.4mg weekly achieved 15% weight loss in the STEP-1 trial[2] with 1,961 participants[2], translating to 33.7 pounds average reduction. Liraglutide 3mg daily showed 8% weight loss in SCALE trials, with participants losing 18.5 pounds on average.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →Gastric emptying delay contributes significantly to these outcomes, with tirzepatide showing the most pronounced effect at 4.5 hours versus semaglutide's 4.1 hours and liraglutide's 3.8 hours. All three medications demonstrate class-wide gastrointestinal side effects, affecting 20-44% of patients with nausea being most common. Tirzepatide users report 31% nausea rates compared to 44% with semaglutide and 39% with liraglutide, despite achieving superior weight loss outcomes.
Clinical Evidence: Head-to-Head Efficacy
Direct comparison studies show tirzepatide 15mg produces 6 percentage points greater weight loss than semaglutide 2.4mg. The SURMOUNT-4[3] maintenance trial demonstrated 25.3% weight loss with tirzepatide versus 9.9% with placebo over 88 weeks.
What Should You Do Next?
If you have questions about which GLP-1 causes most weight loss, FormBlends can help. Our licensed physicians provide personalized guidance based on your medical history and goals. Start with a free online evaluation to connect with a provider who can answer your specific questions.
- Semaglutide for weight loss
- Tirzepatide for weight loss
- Compounded GLP-1 medications
Medical References
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PubMed | ClinicalTrials.gov | DOI]
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. [PubMed | ClinicalTrials.gov | DOI]
Get Personalized Answers
General information is a starting point, but your treatment should be tailored to you. FormBlends connects you with licensed physicians who can evaluate your situation and provide specific recommendations. Complete your free evaluation today.